Alternative primary endpoints for cancer trials needed?

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1645, 2008-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Restoring Confidence in Vaccines by Explaining Vaccine Safety Monitoring: Is a Targeted Approach Needed?

By Casiday Rachel E.

Drug Safety, Vol. 29, Iss. 12, 2006-01 ,pp. : 1105-1109

Adis International

Access to resources Recommend Favorite

Pharmacokinetic Variability of Newer Antiepileptic Drugs: When is Monitoring Needed?

By Johannessen Svein I.

Clinical Pharmacokinetics, Vol. 45, Iss. 11, 2006-01 ,pp. : 1061-1075

Adis International

Access to resources Recommend Favorite

Chemoradiotherapy needed for nonresectable rectal cancer?

Inpharma, Vol. 1, Iss. 1650, 2008-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Is the use of placebos justified in advanced cancer trials?

Inpharma, Vol. 1, Iss. 1548, 2006-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Bicalutamide: an alternative to castration in prostate cancer?

Inpharma, Vol. 1, Iss. 1554, 2006-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite